explore -WSS

explore

author：focus 2025-09-29 18:15:35 - browse：7915

NEW ORLEANS — For some patients suffering with certain blood cancers, CAR-T therapy can offer the tantalizing chance to end their disease with a single treatment.

But the immunotherapy takes time to manufacture, and patients often have to wait weeks to actually receive an infusion once they’re eligible. For some patients with especially aggressive cancer, they can die while waiting for the therapy to arrive.

That’s spurred CAR-T manufacturers to find ways to speed up manufacturing. The industry is testing newer — and possibly better — CAR-T cells that can be made more quickly. Researchers working with Novartis presented Phase 1 clinical trial data Sunday on a new CAR-T cell made with a rapid manufacturing process at the annual American Society of Hematology meeting.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Colonoscopy at 40? Study finds a possible benefit

WSS

Study: Adult vaccinations pay for themselves in societal benefits

Telehealth startups turn to complex chronic diseases

Readout LOUD podcast: What to know about H5N1 bird flu

Apple Watch's A

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

hotspot

explore

knowledge

Duchenne breakthrough therapy leaves behind pioneering families

In areas with more Black doctors, Black people live longer

Bright Health sells Medicare Advantage business to Molina

Why are elite athletes different? Take a look at their microbes

Supreme Court strikes down use of affirmative action

CDC concerned about possible undetected monkeypox spread in U.K.

New air purifier tech could be key to improving indoor air quality

Cloning humans is technically possible. It's curious no one has tried

ChatGPT in medicine: STAT answers readers' burning questions

Do masks work? RCTs can't tell us

leisure time

Medicare says breakthrough device reimbursement rule to come by summer

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Researchers on aging grapple with how to calculate biological age

STAT's guide to the next generation of CAR

CDC wastewater surveillance dashboard to track bird flu hotspots

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

leisure time

explore

leisure time

leisure time